NXTC
NextCure, Inc. NASDAQ Listed May 9, 2019$1.65
+0.00%
vs $1.65
Mkt Cap $4.7M
52w Low $1.65
0.0% of range
52w High $14.27
50d MA $6.80
200d MA $9.74
P/E (TTM)
—
EV/EBITDA
—
P/B
0.1x
Debt/Equity
0.1x
ROE
-159.8%
P/FCF
-0.1x
RSI (14)
15.80
ATR (14)
$0.34
Beta
1.58
50d MA
$6.80
200d MA
$9.74
Avg Volume
133.3K
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
9000 Virginia Manor Road · Beltsville, MD 20705 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -2.26 | -0.81 | +64.2% | 12.76 | -0.2% | -2.9% | +1.0% | +1.6% | +7.0% | -0.6% | — |
| Nov 5, 2025 | AMC | -4.06 | -3.22 | +20.7% | 9.63 | -1.1% | +2.0% | -8.8% | -5.1% | +0.2% | +9.0% | — |
| Aug 7, 2025 | AMC | -4.62 | -11.29 | -144.4% | 5.10 | -3.7% | -4.5% | -1.4% | +0.8% | +7.2% | -0.8% | — |
| May 1, 2025 | AMC | -4.80 | -4.68 | +2.5% | 5.76 | -2.1% | -7.8% | +1.7% | -2.2% | -13.6% | +1.3% | — |
| Mar 6, 2025 | AMC | -4.08 | -4.92 | -20.6% | 8.55 | +4.1% | +5.3% | -2.0% | -5.7% | +3.8% | +0.0% | — |
| Nov 7, 2024 | AMC | -4.20 | -4.92 | -17.1% | 15.84 | +2.3% | -2.3% | +5.4% | +13.2% | -8.4% | -5.0% | — |
| Aug 1, 2024 | AMC | -4.32 | -6.60 | -52.8% | 19.32 | -5.0% | -0.6% | -5.6% | +4.6% | -2.5% | +1.3% | — |
| May 2, 2024 | AMC | -5.40 | -7.32 | -35.6% | 17.88 | +7.4% | +2.7% | +7.8% | -4.2% | +0.0% | +8.9% | — |
| Mar 21, 2024 | AMC | -6.48 | -6.24 | +3.7% | 20.16 | +4.2% | +13.1% | +4.7% | -1.0% | -1.5% | +14.9% | — |
| Nov 2, 2023 | AMC | -7.68 | -6.12 | +20.3% | 14.04 | +0.0% | +0.9% | -0.8% | -2.6% | -0.9% | -5.3% | — |
| Aug 3, 2023 | AMC | -7.20 | -7.68 | -6.7% | 20.64 | -2.9% | -1.2% | +0.0% | +0.6% | -1.2% | +2.4% | — |
| May 4, 2023 | AMC | -7.68 | -6.96 | +9.4% | 19.08 | +0.6% | +0.0% | +1.9% | +7.4% | +0.6% | +1.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 7 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $9.82 | $9.97 | +1.5% | -8.8% | -5.1% | +0.2% | +9.0% | +5.1% |
| Jul 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.90 | $4.82 | -1.6% | -2.9% | +1.3% | +6.4% | -2.7% | -0.2% |
| Jul 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.52 | $5.49 | -0.5% | -5.3% | -1.7% | +1.8% | +1.1% | +3.4% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.27 | $8.40 | +1.6% | -7.0% | -9.8% | +0.1% | +6.0% | -7.2% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.55 | $8.90 | +4.1% | +5.3% | -2.0% | -5.7% | +3.8% | +0.0% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.48 | $16.80 | +8.5% | +5.4% | +13.2% | -8.4% | -5.0% | -2.2% |
| Aug 2 | Needham | Maintains | Buy → Buy | — | $19.32 | $18.36 | -5.0% | -0.6% | -5.6% | +4.6% | -2.5% | +1.3% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.48 | $18.96 | +2.6% | -9.1% | -3.6% | +2.2% | -10.9% | +13.0% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.96 | $19.20 | +1.3% | -2.5% | -9.1% | -3.6% | +2.2% | -10.9% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.88 | $19.20 | +7.4% | +2.7% | +7.8% | -4.2% | +0.0% | +8.9% |
| May 3 | Needham | Maintains | Buy → Buy | — | $17.88 | $19.20 | +7.4% | +2.7% | +7.8% | -4.2% | +0.0% | +8.9% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.16 | $21.00 | +4.2% | +13.1% | +4.7% | -1.0% | -1.5% | +14.9% |
| Mar 20 | Needham | Maintains | Buy → Buy | — | $17.16 | $17.52 | +2.1% | -1.4% | +19.1% | +13.1% | +4.7% | -1.0% |
| Dec 14 | Needham | Maintains | Buy → Buy | — | $17.40 | $12.84 | -26.2% | -19.3% | -5.1% | +0.9% | +5.4% | -3.4% |
| Aug 4 | Needham | Maintains | Buy → Buy | — | $20.64 | $20.04 | -2.9% | -1.2% | +0.0% | +0.6% | -1.2% | +2.4% |
| May 5 | Needham | Maintains | Buy → Buy | — | $19.08 | $19.20 | +0.6% | +0.0% | +1.9% | +7.4% | +0.6% | +1.7% |
| Mar 3 | Needham | Maintains | Buy → Buy | — | $18.84 | $18.96 | +0.6% | -4.5% | +2.0% | -2.6% | +0.7% | -2.0% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $30.12 | $29.64 | -1.6% | -21.1% | -13.6% | -0.6% | -5.3% | +4.3% |
| Nov 4 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $30.12 | $29.64 | -1.6% | -21.1% | -13.6% | -0.6% | -5.3% | +4.3% |
| Nov 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.12 | $29.64 | -1.6% | -21.1% | -13.6% | -0.6% | -5.3% | +4.3% |
| Aug 23 | Truist | Maintains | Buy → Buy | — | $54.12 | $54.12 | +0.0% | -1.6% | +1.4% | +0.0% | -2.2% | -3.0% |
| May 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $45.48 | $45.36 | -0.3% | -1.3% | -5.3% | -0.3% | +2.8% | +9.9% |
| Mar 1 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $58.80 | $59.76 | +1.6% | +0.4% | -1.8% | -1.0% | -0.4% | +0.2% |
| Nov 5 | Needham | Maintains | Buy → Buy | — | $104.64 | $99.00 | -5.4% | -1.3% | -5.0% | -18.3% | -2.8% | +2.0% |
| Mar 5 | Truist | Upgrade | Hold → Buy | — | $136.68 | $145.20 | +6.2% | -0.7% | -3.0% | +7.4% | +1.0% | +1.1% |
| Jan 15 | BofA Securities | Downgrade | Neutral → Underperform | — | $156.84 | $146.64 | -6.5% | -5.8% | -0.9% | +6.3% | -2.9% | +7.9% |
| Jul 16 | Benchmark | Upgrade | Hold → Buy | — | $108.12 | $114.36 | +5.8% | +3.3% | -0.8% | +0.5% | +0.0% | +4.1% |
| Jul 14 | BTIG | Maintains | Buy → Buy | — | $97.80 | $100.80 | +3.1% | +11.4% | -0.8% | +3.3% | -0.8% | +0.5% |
| Jul 13 | SunTrust Robinson Humphrey | Downgrade | Buy → Hold | — | $214.56 | $153.00 | -28.7% | -54.4% | +11.4% | -0.8% | +3.3% | -0.8% |
| Jun 1 | Benchmark | Downgrade | Buy → Hold | — | $374.52 | $364.32 | -2.7% | -4.3% | -4.0% | -6.3% | -2.6% | -2.7% |
| May 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $430.68 | $444.24 | +3.1% | +5.8% | -0.5% | -6.8% | -5.1% | +4.1% |
| Apr 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $458.16 | $457.68 | -0.1% | -8.6% | -0.5% | +7.1% | -0.9% | -1.8% |
| Mar 2 | Roth Capital | Maintains | Buy → Buy | — | $501.12 | $510.36 | +1.8% | +2.6% | -4.1% | +5.7% | -0.2% | -2.0% |
| Jan 13 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $680.40 | $687.60 | +1.1% | -8.3% | +2.4% | +0.1% | -0.7% | -5.3% |
| Dec 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $620.28 | $621.96 | +0.3% | +1.5% | -4.5% | +9.8% | +6.4% | +12.7% |
| Nov 26 | BTIG | Maintains | Buy → Buy | — | $478.08 | $489.60 | +2.4% | +0.3% | +2.5% | +16.8% | -8.8% | +8.3% |
| Nov 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $448.92 | $426.12 | -5.1% | +0.9% | +2.1% | -6.5% | +0.8% | -1.0% |
| Nov 12 | BofA Securities | Maintains | Buy → Buy | — | $468.24 | $467.88 | -0.1% | -4.1% | +0.9% | +2.1% | -6.5% | +0.8% |
| Sep 9 | BofA Securities | Maintains | Buy → Buy | — | $412.08 | $415.20 | +0.8% | +2.9% | +4.1% | +0.1% | +2.4% | -1.7% |
| Sep 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $473.16 | $485.88 | +2.7% | +5.5% | -17.5% | +2.9% | +4.1% | +0.1% |
| Aug 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $290.88 | $299.04 | +2.8% | +10.2% | -6.8% | +3.4% | +3.1% | +1.0% |
| Jul 9 | BofA Securities | Maintains | Buy → Buy | — | $188.76 | $191.88 | +1.7% | +7.8% | -1.8% | +2.2% | -1.4% | -1.3% |
| Jun 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $223.44 | $226.68 | +1.5% | -6.8% | +2.1% | -8.2% | +2.5% | -0.5% |
| Jun 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $223.44 | $226.68 | +1.5% | -6.8% | +2.1% | -8.2% | +2.5% | -0.5% |
No insider trades available.
8-K · 5.02
!!! Very High
NextCure, Inc. -- 8-K 5.02: Executive Change
Jun 25
8-K · 8.01
!! High
NextCure, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 1
8-K
NextCure, Inc. -- 8-K Filing
NextCure expects Phase 2 dose optimization data for its ovarian cancer candidate and Phase 1 updates for LNCB74 in mid-to-late 2026, positioning the company for potential pivotal trial advancement.
Mar 5
Institutional (13F) — Top 15
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Silverarc Capital Management, Llc | 176,057 | $2M | New | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 160,473 | $2M | New | Mar 2026 |
| 3 | Pfizer Inc | 153,354 | $2M | Reduced | Mar 2026 |
| 4 | Renaissance Technologies Llc | 60,534 | $647K | Added | Mar 2026 |
| 5 | Verdad Advisers, Lp | 42,955 | $459K | New | Mar 2026 |
| 6 | Woodline Partners Lp | 27,498 | $294K | New | Mar 2026 |
| 7 | Cardiff Park Advisors, Llc | 21,833 | $233K | — | Mar 2026 |
| 8 | Acadian Asset Management Llc | 18,982 | $199K | Reduced | Mar 2026 |
| 9 | Vanguard Fiduciary Trust Co | 16,015 | $168K | New | Mar 2026 |
| 10 | Citadel Advisors Llc | 15,292 | $161K | New | Mar 2026 |
| 11 | Barclays Plc | 5,626 | $60K | — | Mar 2026 |
| 12 | Ubs Group Ag | 338 | $4K | — | Mar 2026 |
| 13 | Morgan Stanley | 132 | $2K | New | Dec 2025 |
| 14 | Jpmorgan Chase & Co | 61 | $587 | — | Mar 2026 |
| 15 | Bnp Paribas Financial Markets | 32 | $342 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 6
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 12,949 | $165K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 3,634 | $46K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 2,845 | $36K | Feb 2026 |
| 4 | U.S. CORE EQUITY 1 PORTFOLIO | 1,047 | $11K | Jan 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 745 | $9K | Feb 2026 |
| 6 | U.S. CORE EQUITY 2 PORTFOLIO | 733 | $8K | Jan 2026 |
Valuation
Market Cap
$4.7M
Enterprise Value
-$33.0M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.04x
P/B
0.13x
P/S
—
P/FCF
-0.09x
EV/EBITDA
—
Shares Out
2.8M
Financials (TTM)
Revenue
$0
Net Income
-$54.7M
EBITDA
-$52.9M
Free Cash Flow
-$49.6M
Op Cash Flow
-$49.6M
EPS Basic
$-19.65
EPS Diluted
$-19.07
EPS Forward
$-7.91
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$50.2M
Total Liab.
$15.2M
Total Equity
$34.9M
Cash
$41.8M
LT Debt
$4.1M
Book Value/Sh
$12.29
Debt/Equity
0.12x
Current Ratio
4.14
Quick Ratio
4.14
Returns & Growth
ROE
-159.8%
ROA
-111.3%
ROIC
-145.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
+17.7%
Price Returns
2W
-39.5%
1M
-32.7%
3M
-51.3%
6M
-56.0%
12M
+4.9%
Technicals
52W High
$14.27
52W Low
$1.65
50d MA
$6.80
200d MA
$9.74
RSI (14)
15.80
ATR (14)
$0.34
Beta
1.58
Avg Volume
133K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$15.00
High
$15.00
Low
$15.00
Median
$15.00
Data updated apr 26, 2026 4:37pm
· Source: financialmodelingprep.com